2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MPN, CML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

1962 Modeling juvenile myelomonocytic leukemia via base editing using CD34+ cord blood cells

Hanna Shin, PhD, Jose M. Rivera2, Khadija Yousuf3, Kun Jia, PhD4, Julia Meyer, PhD5, Charisa Cottonham, PhD6, Mi Zhou, MD, PhD7, Scott Kogan, MD8, Kyle Cromer, PhD9, Benjamin Braun, MD, PhD10, Elliot Stieglitz, MD11
1 UCSF Benioff Children's Hospitals, San Francisco, California, United States
2 UCSF Benioff Children's Hospitals, San Francisco, California, United States
3 UCSF Benioff Children's Hospitals, San Francisco, California, United States
4 UCSF, San Francisco, California, United States
5 UCSF Benioff Children's Hospitals, San Francisco, California, United States
6 UCSF, San Francisco, California, United States
7 UCSF, San Francisco, California, United States
8 UCSF, San Francisco, California, United States
9 UCSF, San Francisco, California, United States
10 UCSF Benioff Children's Hospitals, San Francisco, California, United States
11 UCSF Benioff Children's Hospitals, San Francisco, California, United States

Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive pediatric myeloid malignancy driven by mutations in the RAS/MAPK signaling pathway, most commonly involving PTPN11, KRAS, NRAS, NF1, and CBL. High-risk cases often harbor mutations with multiple drivers or in cooperating genes such as SETBP1, SHB2, JAK3, or ASXL1. Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy, relapse continues to be the leading cause of treatment failure. Existing genetically engineered mouse (GEM) and patient-derived xenograft (PDX) models have important limitations, including high cost, labor-intensive generation, prolonged experimental timelines, and genetic heterogeneity, highlighting the need for a scalable, versatile, and genetically defined human JMML model.

To address this need, we engineered human umbilical cord blood (CB)-derived CD34⁺ hematopoietic stem and progenitor cells (HSPCs) using CRISPR cytosine base editors (CBEs) to introduce clinically relevant JMML driver mutations, including NF1 R1276*, PTPN11 A72V, and the combined NF1 R1276*/PTPN11 A72V genotype. Edited CB HSPCs were evaluated for granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity in vitro and transplanted into immunodeficient mice to assess human hematopoietic engraftment, clonal expansion, splenomegaly, and overall survival.

Base-edited CB HSPCs carrying JMML driver mutations faithfully recapitulated key disease characteristics both in vitro and in vivo. Mutant cells exhibited GM-CSF hypersensitivity, enhanced human hematopoietic engraftment, progressive expansion of mutant clones following transplantation, splenomegaly, and reduced survival, consistent with hallmark features of JMML observed in established preclinical models.

To evaluate the translational utility of this platform, mice engrafted with NF1 R1276*-mutant JMML cells were treated with the pan-RAS inhibitor RMC-7977, the MEK inhibitor trametinib, or the combination of both agents. Each treatment significantly attenuated JMML-associated phenotypes, including leukemic burden and disease progression. Combination therapy demonstrated enhanced efficacy compared with monotherapy, most notably regarding human cell engraftment.

To further expand the versatility of this platform, we introduced clinically relevant secondary mutations commonly identified in high-risk JMML. Using CBE, we generated SH2B3 R308* with approximately 80% editing efficiency and SETBP1 G870S/D/N variants with approximately 40% efficiency in CB HSPCs. When combined with the primary driver mutations (PTPN11 or NF1), these secondary mutations further enhanced GM-CSF hypersensitivity, supporting their functional contribution to disease progression and demonstrating the feasibility of modeling cooperative mutational events in human HSPCs.

Collectively, these findings establish a rapid, scalable, and genetically defined human JMML model that faithfully recapitulates biological features of the disease while enabling precise interrogation of individual driver and cooperating mutations. Furthermore, the therapeutic efficacy of RMC-7977 and trametinib provides strong preclinical support for targeting the RAS/MAPK signaling pathway in JMML. This platform represents a valuable tool for mechanistic studies, evaluation of targeted therapies, and development of precision medicine strategies for JMML.

Hanna Shin, PhD: No relevant conflicts of interest to declare.